GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ABCL · Jun 30, 2022

AbCellera Biologics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001564590-22-028784General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

68.21% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

594.58% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

66.11% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-18.29% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

58.12% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

26.38% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History18 statesSelf-history eligible
Mar 31, 20220/6 normalizedLevel 3Jun 30, 20220/6 normalizedLevel 3Sep 30, 20220/6 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20235/6 normalizedLevel 3Sep 30, 20235/6 normalizedLevel 3Dec 31, 20235/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Sep 30, 20246/6 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/7 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Increased
Previous
4.58%
Current
68.21%
Delta
63.64%
Cash Generation Increased
Previous
31.66%
Current
594.58%
Delta
562.93%
Growth Increased
Previous
56.15%
Current
66.11%
Delta
9.96%
Profitability Decreased
Previous
71.06%
Current
-18.29%
Delta
-89.34%
R And D Intensity Increased
Previous
8.33%
Current
58.12%
Delta
49.79%
Sbc Intensity Increased
Previous
3.88%
Current
26.38%
Delta
22.50%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ABCL Fundamental State →Transitioned To · ABCL Fundamental State →Transitioned To · ABCL CAPEX_INTENSITY_INCREASED →Transitioned To · ABCL CASH_GENERATION_INCREASED →Transitioned To · ABCL GROWTH_INCREASED →Transitioned To · ABCL PROFITABILITY_DECREASED →Transitioned To · ABCL R_AND_D_INTENSITY_INCREASED →Transitioned To · ABCL SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.